2342 Protein production as an early pharmacodynamics biomarker for RNA-targeting therapies

MLA

Wade K. Self, et al. “2342 Protein Production as an Early Pharmacodynamics Biomarker for RNA-Targeting Therapies.” Journal of Clinical and Translational Science, vol. 2, June 2018, p. 24. EBSCOhost, https://doi.org/10.1017/cts.2018.110.

APA

Wade K. Self, Kathleen Schoch, James Bollinger, Tracy Cole, Holly Kordasiewicz, Randall Bateman, & Timothy Miller. (2018). 2342 Protein production as an early pharmacodynamics biomarker for RNA-targeting therapies. Journal of Clinical and Translational Science, 2, 24. https://doi.org/10.1017/cts.2018.110

Chicago

Wade K. Self, Kathleen Schoch, James Bollinger, Tracy Cole, Holly Kordasiewicz, Randall Bateman, and Timothy Miller. 2018. “2342 Protein Production as an Early Pharmacodynamics Biomarker for RNA-Targeting Therapies.” Journal of Clinical and Translational Science 2 (June): 24. doi:10.1017/cts.2018.110.